This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Estey, E. Search for Related Content PubMed PubMed Citation Articles by Estey, E.

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Elihu Estey

From the Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Elihu Estey, MD, Department of Leukemia, Unit 428, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 61, Houston, TX 77030; e-mail: ehestey{at}mdanderson.org

The median age of patients with acute myeloid leukemia (AML) is 65 to 70 years. The majority of older patients with AML probably do not receive specific treatment, and those who receive standard regimens have a median survival time of less than 1 year. This suggests that, in general, older patients should receive investigational therapy; however, factors other than age influence survival after administration of standard treatment and need to be accounted for when making treatment recommendations. In some cases where investigational therapy is unavailable, palliative care may be the best option. Like AML, myelodysplastic syndrome (MDS) is a disease of the elderly. It is divided into higher and lower risk groups. The natural history of high-risk MDS (eg, > 10% marrow blasts) bears more resemblance to that of AML than to that of an indolent disorder; accordingly, similar therapeutic considerations apply. The more benign natural history of lower risk MDS leads to consideration of reduction in transfusion needs and improvement in quality of life as primary goals of therapy. Lenalidomide, azacitidine, and decitabine, each recently approved by the US Food and Drug Administration, are useful in achieving these objectives.

Author's disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. E. Karp, B. D. Smith, I. Gojo, J. E. Lancet, J. Greer, M. Klein, L. Morris, M. J. Levis, S. D. Gore, J. J. Wright, et al. Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features Clin. Cancer Res., May 15, 2008; 14(10): 3077 - 3082. [Abstract] [Full Text] [PDF]

				M. Yanada, G. Garcia-Manero, G. Borthakur, F. Ravandi, H. Kantarjian, and E. Estey Relapse and death during first remission in acute myeloid leukemia Haematologica, April 1, 2008; 93(4): 633 - 634. [Full Text] [PDF]

				D. Pulte, A. Gondos, and H. Brenner Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century Haematologica, April 1, 2008; 93(4): 594 - 600. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, L. Balducci, and M. Aapro Geriatric Oncology: A Field Coming of Age J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823. [Full Text] [PDF]